id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
cord-286390-ytgw3j4s	Case, James Brett	Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2.	2020-07-03		.txt	text/plain	1674	32	11	Lassa virus entry requires a 676 trigger-induced receptor switch Live attenuated recombinant vaccine 680 protects nonhuman primates against Ebola and Marburg viruses Human immunodeficiency viral vector pseudotyped with the spike envelope of severe acute 684 respiratory syndrome coronavirus transduces human airway epithelial cells and dendritic cells Therapeutic strategies in an outbreak scenario to treat the novel coronavirus 687 originating in Wuhan, China CoV-2 spike pseudotyped virus by recombinant ACE2-Ig Functional assessment of cell entry and receptor 693 usage for SARS-CoV-2 and other lineage B betacoronaviruses Structure of SARS coronavirus spike 696 receptor-binding domain complexed with receptor The Sequence Alignment/Map format and SAMtools A unique strategy for mRNA cap methylation used 703 by vesicular stomatitis virus Angiotensin-converting enzyme 2 is 707 a functional receptor for the SARS coronavirus Intracellular targeting signals contribute to 710 localization of coronavirus spike proteins near the virus assembly site The cytoplasmic tail of the severe acute 713 respiratory syndrome coronavirus spike protein contains a novel endoplasmic reticulum retrieval 714 signal that binds COPI and promotes interaction with membrane protein Synthetic antibodies neutralize SARS-CoV-2 718 infection of mammalian cells Retroviruses pseudotyped with the severe acute respiratory 722 syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting 723 enzyme 2 Enhancing dengue virus maturation using a stable furin over-expressing cell line Establishment and validation of a pseudovirus neutralization assay for Emerging microbes & infections 9 Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-735 reactivity with SARS-CoV Cross-neutralization of SARS-CoV-2 by a human 742 monoclonal SARS-CoV antibody Dipeptidyl peptidase 4 is a functional receptor for the 746 emerging human coronavirus-EMC The coronavirus E protein: assembly and beyond. 749 Viruses Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma A recombinant vesicular stomatitis virus 756 bearing a lethal mutation in the glycoprotein gene uncovers a second site suppressor that 757 restores fusion Specificity, cross-reactivity, and function of 761 antibodies elicited by Zika virus infection Identification of protective epitopes on ebola virus glycoprotein at the 765 single amino acid level by using recombinant vesicular stomatitis viruses Tailored tetravalent antibodies potently and specifically 769 activate Wnt/Frizzled pathways in cells, organoids and mice Human monoclonal antibody 773 combination against SARS coronavirus: synergy and coverage of escape mutants Structural insights into coronavirus entry An efficient method to make human 780 monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus Chimeric Viruses with Vesicular Stomatitis 785 Virus: Actions in the Brain Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein Site-specific 791 glycan analysis of the SARS-CoV-2 spike Efficient recovery of infectious 794 vesicular stomatitis virus entirely from cDNA clones Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-802 SARS-CoV-2 infection of human small intestinal enterocytes Probable Pangolin Origin of SARS-CoV-2 Associated 809 with the COVID-19 Outbreak A pneumonia outbreak associated with a new coronavirus of probable bat 813 origin • Neutralization can be assessed by BSL2 and BSL3 high-throughput assays • SARS-CoV-2 and VSV-SARS-CoV-2-based neutralization assays correlate eTOC Blurb generate a replication-competent vesicular stomatitis virus (VSV) expressing the SARS-CoV-2 spike and compare the neutralizing activity of antibodies with VSV-SARS-CoV-2 to fully infectious SARS-CoV-2.	cache/cord-286390-ytgw3j4s.txt	txt/cord-286390-ytgw3j4s.txt
